*Advancing Adaptive Trial Design Methodology
Past New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $700,000 to $1,500,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- Not on record
- Points of contact
-
- CDRH Acquisition Liaison cdhracquisitions@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Food and Drug Administration is procuring services to develop, standardize, and implement advanced adaptive trial design methodology across three priority areas: Bayesian prior specification and sensitivity analysis frameworks, adaptive trial design applications in rare disease and medical device development, and principled single-arm trial design with robust inferential standards. The estimated solicitation release date is July 1, 2026, with an estimated award date of January 1, 2027.
The estimated award value ranges from $700,000 to $1.5 million. Questions and inquiries should be directed to the FDA's Contracting Officer at cdhracquisitions@fda.hhs.gov.
Forecast text
Provide a description of the investment and the desired outcome. This initiative supports the development, standardization, and implementation of advanced adaptive trial design methodology across three priority areas:(1) Bayesian prior specification and sensitivity analysis frameworks, (2) adaptive trial design applications in rare disease and medical device development, and (3) principled single-arm trial design with robust inferential standards.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast